Thursday, March 26, 2020, 12:00 PM - 1:00 PM, Internet Live, Cincinnati, OH


AMA PRA Category 1 Credits™ (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)

Heart failure (HF) is a complex, progressive clinical condition that currently affects 5.7 million Americans. Its prevalence is predicted to increase by 46% to over 8 million Americans by the year 2030. Accounting for 12 to 15 million outpatient office visits per year, it is one of the most common reasons for hospital admission in patients over the age of 65. Epidemiologic studies in the general population have established that the mean age at first diagnosis of HF (80 years) has been increasing, a trend that is predicted to continue. Older adults are more prone to develop HF due to age-related changes and longer exposure to risk factors.

Despite its high incidence and prevalence, clinicians find HF difficult to diagnose and classify, particularly in older adult patients and/or those with many comorbid disorders. Further, many clinicians are not providing guideline-recommended care. In addition, clinicians may not be familiar with newer agents and their efficacy in certain classes of patients.

Join this Webinar as the faculty provide insights into the challenges of managing older adults with HF.

1. Recognize the signs and symptoms of HF in older adult patients;
2. Select appropriate testing to confirm the diagnosis of HF in older adult patients;
3. Stage and classify (HFrEF vs. HFpEF) a patient’s HF based on their clinical presentation, current guidelines, and diagnostic testing;
4. Describe treatment options, including newly available agents, and consider factors relevant to pharmacotherapy selection for older adult patients with HF;
5. Develop an individualized management strategy for an older adult patient with HF incorporating both pharmacologic and nonpharmacologic interventions.

There are no fees for participating in and receiving CME credit for this online activity. 

To register, click here.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Disclosure / Conflict of Interest Policy

According to the disclosure policy of the University of Cincinnati College of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity.  All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

Staff Disclosures
The University of Cincinnati, American Society of Consultant Pharmacists, Anthony J. Jannetti, Inc. (AJJ), the Gerontological Advanced Practice Nurses Association (GAPNA), Clinical Care Options, LLC, and the peer/content reviewers for this activity have no relevant conflict of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor Critical Care Options, LLC, recommends the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or Critical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement
The opinions expressed during this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

The registration form for this activity is currently unavailable.

This educational activity is supported by an educational grant from Novartis Pharmaceuticals.